Compare ALT & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALT | TRTX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.8M | 660.2M |
| IPO Year | 2005 | 2015 |
| Metric | ALT | TRTX |
|---|---|---|
| Price | $3.20 | $7.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $17.67 | $9.83 |
| AVG Volume (30 Days) | ★ 3.3M | 685.9K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.55% |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | $8.78 |
| Revenue Next Year | N/A | $4.14 |
| P/E Ratio | ★ N/A | $38.37 |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.56 | $7.29 |
| 52 Week High | $6.44 | $9.37 |
| Indicator | ALT | TRTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 22.51 |
| Support Level | $3.18 | N/A |
| Resistance Level | $3.32 | $8.74 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 33.03 | 4.05 |
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.